<?xml version="1.0"?>
<metadata xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dc="http://purl.org/dc/elements/1.1/"><dc:title>Pre-receptor regulation of 11-oxyandrogens differs between normal and cancerous endometrium and across endometrial cancer grades and molecular subtypes</dc:title><dc:creator>Gjorgoska,	Marija	(Avtor)
	</dc:creator><dc:creator>Šturm,	Lea	(Avtor)
	</dc:creator><dc:creator>Lanišnik-Rižner,	Tea	(Avtor)
	</dc:creator><dc:subject>endometrial cancer</dc:subject><dc:subject>11-oxyandrogens</dc:subject><dc:subject>intracrinology</dc:subject><dc:subject>androgen receptor</dc:subject><dc:subject>LC-MS/MS profiling</dc:subject><dc:subject>in vitro models</dc:subject><dc:description>Background: Endometrial cancer (EC) is a prevalent gynecological malignancy globally, with a rising incidence trend. While classic androgens have been implicated with EC risk, the role of their 11-oxygenated metabolites is poorly understood. Here, we studied 11-oxyandrogen formation from steroid precursors in EC for the first time.
Methods: We performed in vitro studies on a panel of four EC cell lines of varying differentiation degree and molecular subtype and a control cell line of normal endometrium to assess 11-oxyandrogen formation from steroid precursors. We also characterized the transcriptomic effects of dihydrotestosterone (DHT) and 11-keto-DHT on Ishikawa and RL95-2. Key molecular players in 11-oxyandrogen metabolism and action were explored in endometrial tumors using public transcriptomic datasets.
Results: We discovered that within endometrial tumors, the formation of 11-oxyandrogens does not occur from classic androgen precursors. However, we observed distinct regulatory mechanisms at a pre-receptor level in normal endometrium compared to cancerous tissue, and between low- and high-grade tumors. Specifically, in vitro models of low-grade EC formed higher levels of bioactive 11-keto-testosterone from 11-oxyandrogen precursors compared to models of noncancerous endometrium and high-grade, TP53-mutated EC. Moreover, the potent androgen, DHT and its 11-keto homologue induced mild transcriptomic effects on androgen receptor (AR)-expressing EC model, Ishikawa. Finally, using public transcriptomic datasets, we found HSD11B2 and SRD5A2, coding for key enzymes in steroid metabolism, to be associated with better disease-specific survival, whereas higher intra-tumoral AR expression correlated with lower recurrence in TP53-wt tumors.
Conclusions: The intra-tumoral metabolism of 11-oxyandrogen precursors is characteristic for low-grade EC of non-TP53-alt molecular subtypes. Our findings support further exploration of circulating 11-oxyandrogens as prognostic biomarkers in EC.</dc:description><dc:date>2024</dc:date><dc:date>2025-01-27 13:54:39</dc:date><dc:type>Članek v reviji</dc:type><dc:identifier>166840</dc:identifier><dc:identifier>UDK: 616-006:577.2</dc:identifier><dc:identifier>ISSN pri članku: 1664-2392</dc:identifier><dc:identifier>DOI: 10.3389/fendo.2024.1404804</dc:identifier><dc:identifier>COBISS_ID: 203016707</dc:identifier><dc:language>sl</dc:language></metadata>
